EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance on Cognitive Screening Tests and Long-Term Substance Use Outcomes in Patients with Polysubstance Use Disorder

Jens Hetland, Egon Hagen, Astri J Lundervold, Aleksander H Erga

European Addiction Research · 2023 · 29 (2) · 150-159

DOI: 10.1159/000528921 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Addiction Research, online erschienen am 20.04.2023. Verfasst von Jens Hetland und 3 weiteren Autor:innen. Beteiligte Einrichtung: KORFOR - Center for Alcohol and Drug Research, Stavanger University Hospital, Stavanger, Norway. Hauptthemen laut MEDLINE: Substance-Related Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cognitive impairments among patients with substance use disorders are prevalent and associated with adverse treatment outcomes. However, knowledge of the predictive value of broad cognitive screening instruments on long-term treatment outcomes is limited. The present study aimed to examine the predictive value of measures from the Montreal Cognitive Assessment® (MoCA®), Wechsler Abbreviated Scale of Intelligence (WASI), and the Behaviour Rating Inventory of Executive Function – Adult version (BRIEF-A) on self-reported long-term substance use and abstinence in patients with polysubstance use disorders (pSUD).

Methods

A cohort (N = 164) of patients with pSUD who started a new treatment sequence in the Stavanger University Hospital catchment area were recruited and followed prospectively for 5 years. Participants completed neurocognitive testing with the MoCA®, WASI, and BRIEF-A at inclusion and were categorized as cognitively impaired or non-impaired according to recommended cut-off values. The sum score of the items from the Drug Use Disorders Identification Test Consumption scale (DUDIT-C) was used as a measure of substance use outcome 1 and 5 years after inclusion. We defined substance abstinence (DUDIT-C = 0) and heavy substance use (DUDIT-C ≥7) to determine whether cognitive impairments measured by the respective instruments were associated with and could predict abstinence and heavy substance use 1 and 5 years after baseline.

Results

At the 1-year follow-up, 54% of the total sample reported total abstinence from substances. Conversely, 31% presented heavy substance use. At 5 years, 64% of the total sample reported abstinence from substances, while 25% presented heavy substance use. The results showed a statistically significant association between cognitive impairment defined from MoCA® and higher continuous scores on DUDIT-C at 1-year follow-up. There were no differences in substance abstinence or heavy substance use between patients with and without cognitive impairment at the 1- and 5-year follow-ups. Furthermore, cognitive impairment did not explain substance abstinence or heavy substance use at the 1- and 5-year follow-ups.

Conclusion

Generally, individuals with pSUD may be burdened and lack psychosocial resources to such an extent that cognitive functioning plays a subordinate role in long-term recovery. The present study suggests that results on screening tools assessing broad cognitive domains at treatment initiation have limited clinical value in predicting long-term substance use outcomes. There is a need to establish clinically viable instruments to assess cognitive functions with well-established clinical and ecological validity in the SUD population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance-Related DisordersAdultHumansNeuropsychological TestsCognitionTreatment OutcomeSelf Report

Stichwörter der Autor:innen

Cognitive impairmentIQMoCAOutcomesSubstance use

Autor:innen und Institutionen

  • KORFOR - Center for Alcohol and Drug Research, Stavanger University Hospital, Stavanger, Norway.
  • Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway.
  • The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.

Zitieren

APA

Hetland, J., Hagen, E., Lundervold, A. J., & Erga, A. H. (2023). Performance on Cognitive Screening Tests and Long-Term Substance Use Outcomes in Patients with Polysubstance Use Disorder. European Addiction Research, 29(2), 150-159. https://doi.org/10.1159/000528921

Vancouver

Hetland J, Hagen E, Lundervold AJ, Erga AH. Performance on Cognitive Screening Tests and Long-Term Substance Use Outcomes in Patients with Polysubstance Use Disorder. European Addiction Research. 2023;29(2):150-159. doi:10.1159/000528921

BibTeX
@article{Hetland2023,
  author = {Hetland, Jens and Hagen, Egon and Lundervold, Astri J and Erga, Aleksander H},
  title = {Performance on Cognitive Screening Tests and Long-Term Substance Use Outcomes in Patients with Polysubstance Use Disorder},
  journal = {European Addiction Research},
  year = {2023},
  volume = {29},
  number = {2},
  pages = {150--159},
  doi = {10.1159/000528921}
}
Kostenlos starten →